National and Kapodistrian University of Athens
Η επίδραση της τεριπαρατίδης στον οστικό μεταβολισμό οστεοπορωτικών μετεμμηνοπαυσιακών γυναικών
Abstract
dc:descriptionAim of the study: Aim of the current study is to evaluate the therapeutical result of Teriparatide (FORSTEO), in comparison with the commonly used and well known drug Alendronate (FOSAMAX) which haw an established therapeutical result, and the individualisation of this therapeutical approach with Teriparatide through the genetic analysis of known genetic polymorphisms and their variations that are related to bone metabolism. Material and methods: The current study is performed in two phases. First we perform a prospective comparative study of teriparatide and alendronate in 50 postmenopausal women with established osteoporosis. These women where randomly dispersed in the two therapeutical schemes. 25 women where used as control. The biochemical and radiological indexes for osteoporosis where measured in 0 time, in 6 months and in 12 months period from the onset of treatment. For the second phase of the current study in the women of the study a analysis of 6 known genetic polymorphisms of bone metabolism (CTR, COL1A1,ESR1PVUII, ESR1XBAI,VDRBSMI,VDRFOKI) was performed with Microarrays method and RT‐PCR. Statistical analysis of the results followed. Results: The results of the women who participated in the current study and received teriparatide showed statistical significant results (p value < 0.05) in improving BMD, Tscore and Zscore both at Lumbar spine and Femoral bone. The same results were obtained for those women that received Alendronate. From the genetic analysis of the women who participated in the study several statistically significant, both positive and negative, correlations where given concerning the presence of different type of polymorphisms and the changes of biochemical and radiological indexes of osteoporosis during treatment. Conclusions: Teriparatide, although it has a different approach, as an anabolic drug, intreating osteoporosis exhibits comparable results to Alendronate, a well known anti – osteoclastic drug, concerning the radiological indexes of osteoporosis. In the current study concerning the effect of genetic polymorphisms during treatment there are some statistical evidence of negative or positive statistical significant results mainly concerning the BMD in Lumbar spine improvement after therapy. More relevant studies have to be performed to have convincing evidence.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Logothetis, Emmanouil
- Λογοθέτης, Εμμανουήλ
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40618